2,420 results match your criteria: "European Institute of Oncology - IRCCS[Affiliation]"
Hematol Rep
December 2024
Oncohematology Division, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Richter syndrome (RS) represents a major unmet need in the lymphoma field, being refractory to chemoimmunotherapy and targeted agents. The BCL-2 inhibitor venetoclax in combination with dose-adjusted EPOCH-R chemoimmunotherapy showed promising efficacy in patients affected by RS. However, responses were not durable, suggesting the need for further treatment optimization.
View Article and Find Full Text PDFAnn Surg Oncol
December 2024
Division of Digestive Surgery IEO, European Institute of Oncology IRCCS, Milan, Italy.
Br J Radiol
December 2024
Breast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
Neoadjuvant Therapy (NT) has become the gold standard for treating locally advanced Breast Cancer (BC). The assessment of pathological response (pR) post-NT plays a crucial role in predicting long-term survival, with Contrast-Enhanced Magnetic Resonance Imaging (MRI) currently recognised as the preferred imaging modality for its evaluation. Traditional imaging techniques, such as Digital Mammography (DM) and Ultrasonography (US), encounter difficulties in post-NT assessments due to breast density, lesion changes, fibrosis, and molecular patterns.
View Article and Find Full Text PDFAnn Surg Oncol
December 2024
Division of Digestive Surgery IEO, European Institute of Oncology IRCCS, Milan, Italy.
Breast
December 2024
Department of Medical Oncology. CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy; Department of Medicine, University of Udine, Udine, Italy.
CDK4/6 inhibitors (CDK4/6i) have significantly impacted on the treatment of HR + HER2 negative (HER2-) metastatic breast cancer (BC) when combined with endocrine therapy. Nonetheless, despite significant research efforts, the mechanisms of de novo and acquired resistance to CDK4/6i have not yet been fully elucidated, highlighting the need for a deeper understanding of these process. Additionally, the importance of dissecting CDK4/6i resistance from endocrine resistance for personalized treatment is increasingly recognized.
View Article and Find Full Text PDFPancreatology
November 2024
Department of Gastroenterology, HagaZiekenhuis Hospital, The Hague, Netherlands. Electronic address:
Objective: In the last decade there has been increasing interest in defining pancreatic steatosis (PS) and establishing its association with pancreatic ductal adenocarcinoma (PDAC). However, no consensus guidelines have yet been published on the management of PS. In this systematic review and meta-analysis performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we investigated the association between PS and PDAC.
View Article and Find Full Text PDFEur Radiol
December 2024
Molecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
Aim: To investigate whether methodological aspects may influence the performance of MRI-radiomic models to predict response to neoadjuvant treatment (NAT) in breast cancer (BC) patients.
Materials And Methods: We conducted a systematic review until March 2023. A random-effects meta-analysis was performed to combine the area under the receiver operating characteristic curve (AUC) values.
BMC Public Health
December 2024
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Lombardia, Italy.
Background: European cancer programmes and policies lack a unified health-related quality of life (HRQoL) assessment tool. The European oncology quality of life toolkit (EUonQoL-Kit) is a novel set of HRQoL questionnaires, co-designed with cancer patients and survivors, translated and culturally adapted into 31 European languages, and with both static and dynamic electronic administration modes. The main aim of this study is the psychometric assessment of the static version.
View Article and Find Full Text PDFCell Metab
December 2024
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy; IFOM ETS, the AIRC Institute of Molecular Oncology, Via Adamello 16, 20139 Milan, Italy. Electronic address:
In preclinical experiments, cyclic fasting-mimicking diets (FMDs) showed broad anticancer effects in combination with chemotherapy. Among different tumor types, triple-negative breast cancer (TNBC) is exquisitely sensitive to FMD. However, the antitumor activity and efficacy of cyclic FMD in TNBC patients remain unclear.
View Article and Find Full Text PDFEur J Cancer
December 2024
Department of Medical Oncology, Institut régional du Cancer de Montpellier (ICM), Montpellier, France; Société Française de Médecine Prédictive et Personnalisée (SFMPP), Montpellier, France; Center for Ecological and Evolutionary Cancer Research (CREEC), Montpellier University, Montpellier, France. Electronic address:
Background: Poly (ADP ribose) polymerase inhibitors (PARPis) are a treatment option for patients with advanced high-grade serous or endometrioid ovarian carcinoma (OC). Recent guidelines have clarified how homologous recombination deficiency (HRD) may influence treatment decision-making in this setting. As a result, numerous companion diagnostic assays (CDx) have been developed to identify HRD.
View Article and Find Full Text PDFDiscov Oncol
December 2024
Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, MI, Italy.
The clinical presentation of T-cell large granular lymphocytic leukemia (T-LGLL) is extremely variable: 30% of patients have neutropenia with no associated symptoms, others present with bacterial infections and sepsis may occur. Tools to predict patient outcome are lacking. Stemming from preliminary results obtained by single cell-RNAseq we investigated by qPCR HSP and IFIT gene families in 27 LGLL patients (23T-LGLL and 4 NK-LGLL), including 11 with neutropenia and/or thrombocytopenia and 16 asymptomatic for the disease.
View Article and Find Full Text PDFRadiol Med
December 2024
Radiation Oncology Unit, Department of Experimental and Clinical Biomedical Sciences, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Purpose: To investigate the awareness and the spread of ChatGPT and its possible role in both scientific research and clinical practice among the young radiation oncologists (RO).
Material And Methods: An anonymous, online survey via Google Forms (including 24 questions) was distributed among young (< 40 years old) ROs in Italy through the yAIRO network, from March 15, 2024, to 31, 2024. These ROs were officially registered with yAIRO in 2023.
Int J Mol Sci
December 2024
Department of Medicine and Surgery, Pathology, Center of Digital Medicine, University of Milano-Bicocca, Fondazione IRCCS San Gerardo dei Tintori, Via Cadore 48, 20900 Monza, Italy.
Follicular-patterned thyroid neoplasms comprise a diverse group of lesions that pose significant challenges in terms of differential diagnosis based solely on morphologic and genetic features. Thus, the identification of easily testable biomarkers complementing microscopic and genetic analyses is a highly anticipated advancement that could improve diagnostic accuracy, particularly for noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTPs). These tumors exhibit considerable morphological and molecular heterogeneity, which may complicate their distinction from structurally similar neoplasms, especially when genetic analyses reveal shared genomic alterations (e.
View Article and Find Full Text PDFDiagnostics (Basel)
December 2024
Breast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Background: Diabetic Mastopathy (DMP) is an uncommon benign fibro-inflammatory condition that occurs in women with long-standing diabetes mellitus (DM), particularly type 1. It often mimics breast cancer (BC) in clinical and imaging presentations, leading to diagnostic challenges.
Methods: A retrospective monocentric study was conducted, analyzing clinical, radiologic, and pathological data from 28 women diagnosed with DMP over 10 years at the European Institute of Oncology.
Cancers (Basel)
December 2024
Pathology Unit, Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, 16132 Genoa, Italy.
The Esophageal Adenocarcinoma Study Group Europe (EACSGE) recently proposed a granular histologic classification of esophageal-esophago-gastric junctional adenocarcinomas (EA-EGJAs) based on the study of naïve surgically resected specimens that, when combined with the pTNM stage, is an efficient indicator of prognosis, molecular events, and response to treatment. In this study, we compared histologic classes of endoscopic biopsies taken before surgical resection with those of the surgical specimen, to evaluate the potential of the EACSGE classification at the initial diagnostic workup. A total of 106 EA-EGJA cases with available endoscopic biopsies and matched surgical resection specimens were retrieved from five Italian institutions.
View Article and Find Full Text PDFCancers (Basel)
November 2024
Oncology Department, E.O. Ospedali Galliera, 16128 Genoa, Italy.
Background/objectives: Our previous study of 291 cancer patients, we showed that 20% did not respond to two doses of COVID-19 vaccine administered six weeks apart.
Methods: Here, we investigated if psychological factors (distress, anxiety, and depressive symptoms) affected antibody response and markers of vaccine activation (D-dimer) after 6 months from initial vaccination.
Results: Overall, 31 subjects (14.
Eur J Cancer
December 2024
Digestive Surgery, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti, 435, Milan 20141, Italy. Electronic address:
Support Care Cancer
December 2024
Department of Oncology and Hemato-Oncology, University of Milan, Via Santa Sofia 9/1, 20122, Milan, Italy.
Purpose: Caregiving is a crucial but frequently overlooked part of cancer care, as well as the main emotions experienced by caregivers during that journey. This qualitative study aimed to explore the emotional landscape of informal caregivers in supporting breast cancer survivors (BCs) living with chronic pain (CP).
Methods: We conducted 3 focus groups with informal caregivers of BCs with CP.
Comput Struct Biotechnol J
December 2024
Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
The tumor suppressor is frequently mutated in hormone receptor-negative, HER2-positive breast cancer (BC), contributing to tumor aggressiveness. Traditional ancillary methods like immunohistochemistry (IHC) to assess functionality face pre- and post-analytical challenges. This proof-of-concept study employed a deep learning (DL) algorithm to predict mutational status from H&E-stained whole slide images (WSIs) of BC tissue.
View Article and Find Full Text PDFOncologist
December 2024
Département d'Oncologie Médicale, Institut Paoli-Calmettes, Marseille, France.
Background: In PAOLA-1/ENGOT-ov25, the addition of olaparib to bevacizumab maintenance improved overall survival in patients with newly diagnosed advanced ovarian cancer. We describe the safety profile and quality of life (QoL) of this combination in older patients in PAOLA-1.
Methods: Safety (CTCAE v4.
Nat Commun
December 2024
School of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
Anti-disialoganglioside (GD2) antibody therapy has provided clinical benefit to patients with neuroblastoma however efficacy is likely impaired by the immunosuppressive tumor microenvironment. We have previously defined a link between intratumoral copper levels and immune evasion. Here, we report that adjuvant copper chelation potentiates anti-GD2 antibody therapy to confer durable tumor control in immunocompetent models of neuroblastoma.
View Article and Find Full Text PDFJ Clin Oncol
December 2024
Harvard Medical School, Massachusetts General Hospital, Boston, MA.
Olaparib treatment significantly improved objective response rate (primary end point) and progression-free survival versus nonplatinum chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer in the open-label phase III SOLO3 trial (ClinicalTrials.gov identifier: NCT02282020). We report final overall survival (OS; prespecified secondary end point), post hoc OS analysis by number of previous chemotherapy lines, and exploratory BRCA reversion mutation analysis.
View Article and Find Full Text PDFAm J Otolaryngol
December 2024
Department of Otolaryngology and Head and Neck Surgery, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Purpose: Transoral laser microsurgery is the mainstay in treating early-stage laryngeal squamous cell carcinoma. However, consensus is lacking in non-radical surgery for infiltrating cancer, and even doubts are cast for patients with laryngeal dysplasia at the resection margins. In this study we aim to assess the prognostic significance of laryngeal dysplasia at the surgical margins in patients radically treated for infiltrating cancer.
View Article and Find Full Text PDFGlob Reg Health Technol Assess
December 2024
Department of Health Economics and Outcomes Research, AdRes Health Economics & Outcomes Research, Turin - Italy.
Objective: A per-patient cost of therapy administration model was developed to estimate the cost of mosunetuzumab vs. tisagenlecleucel in patients with relapsing or refractory follicular lymphoma (R/R FL) receiving two or more lines of systemic therapy (3L+) from both the Italian hospital and societal perspectives.
Methods: A per-patient total cost of therapy administration model was developed to compare the resource consumption of two treatments - mosunetuzumab and tisagenlecleucel.